COMP <GO>
NNNN vs UNH // RETURN ON INVESTED CAPITAL (ROIC)
Anbio Biotechnology (Class A) (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: NNNN 3
— UNH 9
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: NNNN
LAST: $3.72 (-3.12%) • MKT CAP: $535.3M
roic
17.00%
LAST: $410.91 (+0.94%) • MKT CAP: $368.83B
roic
11.47%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NNNN VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NNNN | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 87.20% | 88.57% | -1.37 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 17.00% | 11.47% | +5.53 | NNNN | /roic <GO> |
| EV/EBITDA & P/E Valuation | 91.5x | 16.4x | +75.05 | UNH | /valuation <GO> |
| Free Cash Flow Yield | -1.26% | 6.48% | -7.74 | UNH | /fcf-yield <GO> |
| Operating Margin | 66.70% | 4.82% | +61.88 | NNNN | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 3.14% | +64.86 | NNNN | /net-margins <GO> |
| Revenue Growth (YoY) | 5.60% | 6.46% | -0.86 | UNH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 3.12 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 37.9 | 59.2 | -21.30 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 77.7x | 17.7x | +59.96 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $535.3M | $368.83B | -$368.30B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NNNN REV | UNH REV | NNNN GROSS % | UNH GROSS % | NNNN FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $8.6M | $447.57B | 87.2% | 88.7% | -$6.7M | $16.07B |
| FY 2024 | $8.2M | $400.28B | 71.9% | 88.3% | $2.1M | $20.70B |
| FY 2023 | $6.7M | $371.62B | — | 89.6% | $898.4K | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NNNN // BETA —
UNH // BETA 0.33